Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic …

G Ntaios, V Papavasileiou, K Makaritsis, K Vemmos… - Stroke, 2017 - Am Heart Assoc
Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis

Y Bai, H Deng, A Shantsila, GYH Lip - Stroke, 2017 - Am Heart Assoc
Background and Purpose—This study was designed to evaluate the effectiveness and
safety of rivaroxaban in real-world practice compared with effectiveness and safety of …

Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions

SV Wang, SK Sreedhara, S Schneeweiss - Nature communications, 2022 - nature.com
Studies that generate real-world evidence on the effects of medical products through
analysis of digital data collected in clinical practice provide key insights for regulators …

Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation

DJ Graham, E Baro, R Zhang, J Liao… - The American Journal of …, 2019 - Elsevier
Background Nonvitamin K antagonist oral anticoagulants (NOACs) are alternatives to
warfarin in patients with nonvalvular atrial fibrillation. Randomized trials compared NOACs …

Strengths and weaknesses of 'real-world'studies involving non-vitamin K antagonist oral anticoagulants

AJ Camm, KAA Fox - Open Heart, 2018 - openheart.bmj.com
Randomised controlled trials (RCTs) provide the reference standard for comparing the
efficacy of one therapy or intervention with another. However, RCTs have restrictive …

[HTML][HTML] How I treat CLL patients with ibrutinib

JR Brown - Blood, 2018 - Elsevier
Ibrutinib is a transformative therapy for high-risk and relapsed refractory chronic lymphocytic
leukemia (CLL) patients. In clinical trials in relatively healthy younger patients, ibrutinib has …

Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis

ZC Gu, AH Wei, C Zhang, XH Wang, L Zhang… - Clinical …, 2020 - Elsevier
Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Implementation and validation of the 2013 Caprini score for risk stratification of arthroplasty patients in the prevention of venous thrombosis

ES Krauss, A Segal, MA Cronin… - Clinical and Applied …, 2019 - journals.sagepub.com
Appropriate chemoprophylaxis choice following arthroplasty requires accurate patient risk
assessment. We compared the results of our prospective department protocol to the Caprini …

Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients

S Deitelzweig, X Luo, K Gupta, J Trocio… - … medical research and …, 2017 - Taylor & Francis
Objective: To compare the risk of stroke/systemic embolism (S/SE) and major bleeding (MB)
of elderly (≥ 65 years of age) nonvalvular atrial fibrillation (NVAF) patients initiating …

Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis

EM Weinberg, J Palecki… - Seminars in Liver Disease, 2019 - thieme-connect.com
Direct-acting oral anticoagulants (DOACs) have provided benefit in patients requiring
anticoagulation for certain diseases by decreasing the burden of subcutaneous injections …